50 - SER-109, an Oral Investigational Microbiome Therapy for the Prevention of Recurrent Clostridioides difficile Infection. Seres Therapeutics

Speaker(s)

• BM

  Barbara McGovern, MD

  Vice President
  Seres Therapeutics, Inc.
  Cambridge, MA, United States

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.